Immunodeficiency 69 (IMD69) Cell Models for Research

Immunodeficiency 69 (IMD69) is a rare primary immunodeficiency disorder caused by mutations in the ZAP70 gene. It is characterized by a selective deficiency of CD8+ T cells and impaired T cell receptor (TCR) signaling, leading to recurrent infections, autoimmune manifestations, and increased susceptibility to malignancies. The exact prevalence is unknown, but it is estimated to affect less than 1 in 1,000,000 individuals worldwide. Without early diagnosis and treatment, the condition is often fatal in childhood. Hematopoietic stem cell transplantation is the only curative therapy, but it carries significant risks. The clinical heterogeneity and rarity of IMD69 make it a challenging condition to study, yet it provides a unique opportunity to understand fundamental aspects of T cell development and signaling.

IMD69 serves as an excellent model for studying T cell receptor signaling, thymic selection, and immune tolerance. The ZAP70 protein is a critical kinase in the TCR signaling cascade, and its loss or dysfunction leads to profound immune defects. Research on IMD69 has contributed to our understanding of how TCR signals are transduced and how they regulate T cell development and function. Additionally, IMD69 provides a model for investigating the molecular basis of autoimmune diseases and immunodeficiencies. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and the European Society for Immunodeficiencies (ESID), provide clinical and genetic information that can be leveraged for mechanistic studies. Open questions include the role of ZAP70 in other cell types, the potential for gene therapy, and the development of targeted therapies.

While IMD69 is primarily an immunodeficiency, it is associated with an increased risk of certain cancers, particularly lymphomas and leukemias. The major pathways involved include:

• • TCR signaling pathway: ZAP70 is essential for TCR signal transduction. Upon TCR engagement, ZAP70 is recruited to the phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs) of the TCR complex, where it phosphorylates downstream adaptors such as LAT and SLP-76. This leads to activation of multiple signaling cascades, including the Ras-MAPK pathway, NF-κB pathway, and calcium mobilization.
• • Apoptosis and survival: Defective TCR signaling can impair thymic selection, leading to the survival of autoreactive T cells and increased risk of autoimmunity. Additionally, impaired apoptosis of lymphocytes may contribute to lymphoproliferation and malignancy.
• • DNA damage response: Some ZAP70 mutations may affect DNA repair mechanisms, increasing genomic instability and cancer susceptibility.

Data from ClinVar and literature reports.

The primary deregulated network is the TCR signaling pathway. Key nodes include:

• • ZAP70: The central kinase; its loss abrogates downstream signaling.
• • LAT: A scaffold protein that is phosphorylated by ZAP70; its phosphorylation is essential for signal propagation.
• • SLP-76: Another adaptor that links TCR signaling to actin polymerization and calcium flux.
• • PLCγ1: Activated by SLP-76, leading to inositol trisphosphate (IP3) production and calcium release.
• • Ras-MAPK pathway: Activated via GRB2-SOS, leading to ERK phosphorylation and gene transcription.
• • NF-κB pathway: Activated via PKCθ and CARMA1, leading to inflammatory cytokine production.
• • Calcium-NFAT pathway: Calcium influx activates calcineurin, which dephosphorylates NFAT, allowing its nuclear translocation and gene transcription.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate T cell development and are useful for studying ZAP70 function in a more physiologically relevant context.

• • ZAP70 knockout mice: These mice exhibit a phenotype similar to human IMD69, with a block in T cell development at the double-positive stage. They are valuable for studying TCR signaling and testing therapeutic interventions.
• • ZAP70 knock-in mice with patient-specific mutations: These models allow the study of specific mutations in vivo.
• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient-derived immune cells can be used to study disease mechanisms and drug responses.

CRISPR-Cas9 gene editing enables the generation of isogenic cell lines with specific ZAP70 mutations, providing powerful tools for functional studies. For example:

• • ZAP70 knockout cell lines: Created by introducing frameshift mutations in the ZAP70 gene, these lines completely lack ZAP70 protein and recapitulate the loss-of-function phenotype. They are useful for studying the consequences of ZAP70 deficiency on TCR signaling and T cell function.
• • ZAP70 point-mutation knock-in lines: These lines carry specific patient-derived mutations (e.g., R192W, P80Q) and allow the study of how different mutations affect ZAP70 function.

These engineered cell models are commercially available and sequence-verified, ensuring reproducibility and accelerating research. They can be used in high-throughput screens to identify compounds that restore TCR signaling or inhibit downstream oncogenic pathways.

Gene-edited cell lines are essential for validating the functional impact of ZAP70 mutations. For example, by comparing wild-type and ZAP70 knockout Jurkat cells, researchers can identify genes that are differentially expressed upon TCR stimulation, revealing downstream targets of ZAP70. Similarly, knock-in lines with specific mutations can be used to assess the effect of those mutations on protein stability, kinase activity, and downstream signaling.

Isogenic pairs (wild-type vs. knockout) are invaluable for drug screening. For instance, a ZAP70 knockout cell line can be used to identify compounds that bypass ZAP70 deficiency and restore T cell activation. Conversely, knock-in lines with activating mutations (if any) could be used to screen for inhibitors that block aberrant signaling. These models also help in studying resistance mechanisms to immunomodulatory drugs.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of ZAP70-deficient cells but not wild-type cells. These genes could serve as potential therapeutic targets. Additionally, by comparing the proteomic or transcriptomic profiles of wild-type and mutant cells, novel biomarkers for disease diagnosis or prognosis can be discovered.